|A unique collection of 60 Toxicity natural compounds for screening|
|Catalog No:||Bb201|| Toxicity Compound Library
|Size:||1mg/well * 60 Compounds|
2mg/well * 60 Compounds
1. Petasitenine has toxicity, the toxic effect will be developed in the tissues other than the liver or in the species apart from rodents.
2. Petasitenine has carcinogenic activity.
1. Khellin has anti-inflammatory and analgesic properties.
2. Khellin exhibits significant Epidermal Growth Factor Receptor (EGFR) inhibitory activity.
3. Khellin may be beneficial in the management of kidney stone disease caused by hyperoxaluria.
4. Khellin and visnagin can prevent renal epithelial cell damage caused by oxalate (Ox) and calcium oxalate monohydrate (COM) and can therefore play a potential role in the prevention of stone formation associated with hyperoxaluria.
5. KUVA (khellin plus ultraviolet A) stimulates proliferation and melanogenesis in normal human melanocytes and melanoma cells in vitro.
6. Khellin and visnagin has genotoxicity of the natural furochromones.
7. Khellin, as photosensitizer, together with ultraviolet A (UVA) irradiation, it can treat vitiligo patients; it does not induce skin phototoxicity with UVA but it induces repigmentation similar to psoralens; khellin does not lead to phototoxic skin erythema and thus can be considered safe for home treatment.
1. Humantenmine is a toxic compound isolated from Gelsemium elegans Benth .
2. Humantenmine and koumine may inhibit several CYP450 enzyme activities.
1. Senaetnine possesses mild alkylating reactivity, and the evidence indicates that it can cause moderate tissue injury without the need for metabolic activation.
1. Dihydrotanshinone I has antibacterial activity against a broad range of Gram positive bacteria, it generates superoxide radicals in Bacillus subtilis lysates, the superoxide radicals are important in the antibacterial actions of the agents.
2. Dihydrotanshinone I induces topoisomerase I-mediated DNA cleavage as strongly as camptothecin, it inhibits the catalytic activity of topoisomerase I by the formation of a cleavable complex and at least in part through the intercalation into DNA.
3. Dihydrotanshinone I has cytotoxicity to a variety of tumor cells, it induces a potent cytotoxicity to human umbilical vein endothelial cells with an IC 50 value of approximately 1.28 ug/ml.
4. Dihydrotanshinone I has a potential to be developed as a novel anti-angiogenic agent, it can inhibit angio-genesis through suppressing endothelial cell proliferation, migration, invasion and tube formation.
5. Dihydrotanshinone I could be a valuable candidate for the intervention of NF-κB-dependent pathological conditions such as inflammation and cancer.
6. Dihydrotanshinone I induces cell growth arrest during the S phase and subsequently, apoptosis, following its application to K562/ADR cells, exhibits cytotoxicity against various tumor cell lines.
7. Dihydrotanshinone I combines irradiation, which can enhance apoptotic effects in human cervical cancer by HPV E6 down-regulation and caspases activation.
8. Dihydrotanshinone I and cryptotanshinone exhibit strong inhibition towards human liver microsome (HLM)-catalyzed propofol glucuronidation, and dihydrotanshinone I exhibits strong inhibition towards UDP-glucuronosyltransferase (UGT) 1A7.
9. Dihydrotanshinone I interferes with the RNA-binding activity of HuR affecting its post-transcriptional function.
10. Dihydrotanshinone I induces caspase and ROS dependent apoptosis and autophagy,